No Data
*Special Treat Longjin (002750.SZ): The holding subsidiary has obtained the Pharmaceutical registration certificate.
On January 3, Glonghui reported that *ST Longjin (002750.SZ) announced that its holding subsidiary Yunnan Longjin Kangyou Biomedical Co., Ltd. recently received the drug registration certificate for Ezetimibe tablets issued by the National Medical Products Administration (Certificate No.: 2024S30289). Ezetimibe tablets are cholesterol absorption inhibitors, initially developed in collaboration with Merck and Schering-Plough, and were approved for import into China in 2006. The original research compound patent in China expired in 2022, and it is mainly used clinically to treat primary hypercholesterolemia and homozygous familial hypercholesterolemia.
Special treat Longjin (002750.SZ): Received the pharmaceutical registration certificate for sildenafil citrate orally disintegrating tablets.
*ST Longjin (002750.SZ) announced that the company's controlling subsidiary yunnan Longjin Kangyou Biomedical Co., Ltd.
*ST Longjin: 2024 Third Quarter Report
*ST Longjin: 2024 Semi-Annual Report Summary
*ST Longjin: 2024 Semi-Annual Report
ST Longjin (002750.SZ): Net loss of 4.224 million yuan in the first half of the year.
Geelong reported its semi-annual report for 2024 on August 27th. The report shows a revenue of 39.4178 million yuan for the reporting period, a decrease of 9.66% year-on-year. The net income attributable to the company's shareholders is -4.224 million yuan, with a narrowed loss year-on-year. The net income attributable to the company's shareholders after deducting non-recurring gains and losses is -11.4206 million yuan. The basic earnings per share is -0.0105 yuan.
Kunming Longjin Pharmaceutical Co., Ltd.'s (SZSE:002750) Share Price Not Quite Adding Up